Document:

Global Note

 Exhibit 4.8 
 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF
CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (AND ANY PAYMENT HEREON IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE
OF THE DEPOSITORY TRUST COMPANY), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL SINCE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 
 TRANSFERS OF THIS GLOBAL SECURITY SHALL BE LIMITED TO TRANSFERS TO NOMINEES OF THE DEPOSITORY TRUST COMPANY, OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR’S NOMINEE
AND TRANSFERS OF PORTIONS OF THIS GLOBAL SECURITY SHALL BE LIMITED TO TRANSFERS MADE IN ACCORDANCE WITH THE RESTRICTIONS SET FORTH IN ARTICLE TWO OF THE INDENTURE REFERRED TO ON THE REVERSE HEREOF. 
 The foregoing legend may be removed from this Security on satisfaction of the conditions specified in the Indenture. 

 NABI BIOPHARMACEUTICALS 
 2.875% Convertible Senior Notes due 2025 
  

			
	No.: R-1	 	CUSIP: 629519 AB 5
	Issue Date: April 19, 2005	 	Principal Amount: $0.00
	Issue Price: $1,000 (for each $1,000 Principal Amount)	 	

 Nabi Biopharmaceuticals, a Delaware corporation, promises to pay to Cede & Co. or
registered assigns, the principal amount of ZERO DOLLARS AND NO CENTS ($0.00) on April 15, 2025 or such greater or lesser amount as is indicated on the Schedule of Increases and Decreases of Global Security attached to this Security.

 Interest Payment Dates: April 15 and October 15, commencing October 15, 2005. 
 Record Dates: April 1 and October 1. 
 Reference is hereby made to the further provisions of this Security set forth on the reverse side of this Security, which further provisions shall for all purposes have the same effect as if set forth at this place. 
  

 F-2 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed under its corporate seal.

 Dated: August 10, 2005 
  

			
	NABI BIOPHARMACEUTICALS
		
	By:	 	 /s/ Mark L. Smith

	Name:	 	Mark L. Smith
	Title:	 	 Senior Vice President, Finance,
 Chief Financial
Officer, Chief
 Accounting Officer, and Treasurer

 TRUSTEE’S CERTIFICATE OF AUTHENTICATION 
 U.S. BANK NATIONAL ASSOCIATION 
 as Trustee, certifies that this is one of the Securities 
 referred to in the within mentioned Indenture. 
  

			
	By:	 	 /s/ David Ganss

		 	Authorized Signatory

 Dated: August 10, 2005 
  

 F-3 

 REVERSE OF NOTE 
 2.875% Convertible Senior Notes due 2025 
 This Security is one of a duly authorized issue of the
2.875% Convertible Senior Notes due 2025 (the “Securities”) of Nabi Biopharmaceuticals, a Delaware corporation (including any successor corporation under the Indenture hereinafter referred to, the “Company”), issued
under an Indenture, dated as of April 19, 2005 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee (the “Trustee”). The terms of the Security include those stated in the
Indenture, those made part of the Indenture by reference to the Trust Indenture Act of 1939, as amended (“TIA”), and those set forth in this Security. This Security is subject to all such terms, and Holders are referred to the
Indenture and the TIA for a statement of all such terms. To the extent permitted by applicable law, in the event of any inconsistency between the terms of this Security and the terms of the Indenture, the terms of the Indenture shall control.
Capitalized terms used but not defined herein have the meanings assigned to them in the Indenture referred to below unless otherwise indicated. 
 1.
Interest. 
 The Company promises to pay interest on the principal amount of the Securities at the interest rate of 2.875% per annum
(the “Interest Rate”) from the date of issuance until repayment in full at April 15, 2025, or until an earlier conversion, redemption or repurchase. The Company will pay interest on this Security semi-annually in arrears on
April 15 and October 15 of each year (each, an “interest payment date”), commencing October 15, 2005. 
 The
Securities shall bear interest from April 19, 2005 until the principal amount thereof is paid or made available for payment, or until such date on which the Securities are converted, redeemed or purchased as provided herein at the Interest
Rate. 
 Interest on the Securities shall be computed (i) for any full semi-annual period for which the Interest Rate is applicable, on
the basis of a 360-day year of twelve 30-day months and (ii) for any period for which the Interest Rate is applicable for less than a full semi-annual period for which interest is calculated, on the basis of a 30-day month and, for such periods
of less than a month, the actual number of days elapsed over a 30-day month. 
 If this Security is redeemed or repurchased by the Company on
a date that is after the record date and on or prior to the corresponding interest payment date, interest and Liquidated Damages, if any, accrued and unpaid hereon to but not including the applicable Redemption Date, Repurchase Date or Fundamental
Change Purchase Date, as the case may be, will be paid to the same Holder to whom the Company pays the principal of this Security. 
 Interest on Securities converted after a record date but prior to the corresponding interest payment date will be paid to the Holder of the Securities on the record date but, upon conversion, the Holder must pay the Company the interest and
Liquidated Damages, if any, which have accrued and will be paid on such interest payment date; provided, that no such payment need be made with respect to Securities which will be redeemed or repurchased by the Company after a record date and
on or prior to the third Business Day after the corresponding interest payment date. 
  

 R-1 

 If the principal amount hereof or any portion of such principal amount or any interest, including
Liquidated Damages, if any, on any Security is not paid when due (whether upon acceleration pursuant to Section 6.2 of the Indenture, upon the date set for payment of the Redemption Price pursuant to Section 3.1 of the Indenture or the
Repurchase Price or the Fundamental Change Purchase Price pursuant to Section 3.7 or Section 3.11 of the Indenture, as the case may be, or upon the Stated Maturity of this Security), then in each such case the overdue amount shall, to the
extent permitted by law, bear interest at the Interest Rate, compounded semi-annually, which interest shall accrue from the date on which such overdue amount was originally due until the date on which payment of such amount, including interest
thereon, has been made or duly provided for. All such interest shall be payable on demand. 
 2. Method of Payment. 
 Except as provided below, interest will be paid (i) on the Global Securities to The Depository Trust Company (“DTC”) or its nominee
in immediately available funds, (ii) on any definitive Securities having an aggregate principal amount of $2,000,000 or less, by check mailed to the Holders of such Securities, and (iii) on any definitive Securities having an aggregate
principal amount of more than $2,000,000, by wire transfer in immediately available funds at the election of the Holders of such Securities. 
 At Stated Maturity, the Company will pay interest on definitive Securities at the Company’s office or agency in New York City, which initially will be the corporate trust office of U.S. Bank National Association, in New York City.

 Principal on Global Securities will be paid to DTC or its nominee in immediately available funds. Principal on definitive Securities will
be payable, upon Stated Maturity or when due, at the office or agency of the Company in New York City, maintained for such purpose, initially the corporate trust office of U.S. Bank National Association, in New York City. 
 Subject to the terms and conditions of the Indenture, the Company will make payments in cash in respect of Redemption Prices, Repurchase Prices,
Fundamental Change Purchase Prices and at Stated Maturity to Holders who surrender Securities to a Paying Agent to collect such payments in respect of the Securities. The Company will pay cash amounts in money of the United States that at the time
of payment is legal tender for payment of public and private debts. However, the Company may make such cash payments by check payable in such money, subject to the terms of the Indenture. 
 3. Paying Agent, Conversion Agent and Registrar. 
 Initially, U.S. Bank National Association will act as Paying Agent, Conversion Agent and Registrar. The Company may appoint and change any Paying Agent, Conversion Agent or Registrar without notice, other than notice to the Trustee;
provided that the Company will maintain at least one Paying Agent in the State of New York, City of New York, Borough of Manhattan, which shall initially be an office or agency of the Trustee. The Company or any of its Subsidiaries or any of
their Affiliates may act as Paying Agent, Conversion Agent or Registrar. 
  

 R-2 

 4. Indenture. 
 The Securities are senior unsecured obligations of the Company initially limited to $100,000,000 aggregate principal amount (or such greater amount necessary to reflect the exercise by the Initial Purchasers of their option to purchase
additional Securities in compliance with the Purchase Agreement, but not in excess of $120,000,000). 
 The Company may, without the consent
of the Holders of the Securities, increase the Principal Amount of the Securities by issuing additional securities in the future on the same terms and conditions, except for any differences in the issue price and interest accrued prior to the issue
date of the additional securities, provided, that such difference does not cause the additional securities to constitute a different class of securities than the Securities for U.S. federal income tax purposes, and provided further, that the
additional securities have the same CUSIP number as the Securities. The Securities and any additional securities would rank equally and ratably and would be treated as a single class for all purposes under the Indenture. No additional securities may
be issued if any Event of Default has occurred with respect to the Securities. The Indenture does not limit other indebtedness of the Company, secured or unsecured. 
 5. Redemption at the Option of the Company. 
 No sinking fund is provided for the Securities. The
Securities are not redeemable by the Company prior to April 18, 2010. On or after April 18, 2010, the Securities will be redeemable for cash at the option of the Company, in whole or in part, at any time or from time to time, upon not less
than 30 nor more than 60 days’ notice by mail for a redemption price equal to the principal amount of those Securities plus accrued and unpaid interest, including Liquidated Damages, if any, on those Securities to, but not including, the
Redemption Date (the “Redemption Price”) as set forth in the Indenture. 
 6. Purchase By the Company at the Option of the Holder.

 Subject to the terms and conditions of the Indenture, the Company shall become obligated to purchase, at the option of the Holder, the
Securities held by such Holder on April 15, 2010, April 15, 2012, April 15, 2015 and April 15, 2020 at a Repurchase Price equal to the principal amount of such Securities on the applicable Repurchase Date plus accrued
and unpaid interest, including Liquidated Damages, if any, to, but not including, the Repurchase Date, upon delivery of a Repurchase Notice containing the information set forth in the Indenture, at any time from the opening of business on the date
that is 20 Business Days prior to such Repurchase Date until the close of business on the Business Day preceding such Repurchase Date and upon delivery of the Securities or the required transfer to the Paying Agent by the Holder as set forth in the
Indenture. 
 At the option of the Holder and subject to the terms and conditions of the Indenture, the Company shall become obligated to
offer to purchase the Securities held by such Holder for a Fundamental Change Purchase Price equal to the principal amount of such Securities plus accrued and unpaid interest, including Liquidated Damages, if any, to, but not including, the
Fundamental Change Purchase Date. The Fundamental Change Purchase Date, which shall be determined by the Company, shall be between 30 and 60 days of the Company’s delivery of the notice describing such Fundamental Change and the resulting
repurchase right. The Fundamental Change Purchase Price shall be paid in accordance with the Indenture. 
  

 R-3 

 Holders have the right to withdraw any Repurchase Notice or Fundamental Change Purchase Notice, as the
case may be, by delivering to the Paying Agent a written notice of withdrawal in accordance with the provisions of the Indenture. 
 If cash
sufficient to pay the Repurchase Price or the Fundamental Change Purchase Price, as the case may be, of all Securities, or portions thereof to be purchased as of the Repurchase Date or the Fundamental Change Purchase Date, as the case may be, is
deposited with the Paying Agent on the Business Day following the Repurchase Date or the Fundamental Change Purchase Date, as the case may be, interest will cease to accrue on such Securities (or portions thereof) immediately after such Repurchase
Date or Fundamental Change Purchase Date, as the case may be, and the Holder thereof shall have no other rights as such other than the right to receive the Repurchase Price or the Fundamental Change Purchase Price upon surrender of such Security.

 7. Notice of Redemption. 
 Notice of
redemption pursuant to Section 3.1 of the Indenture of this Security will be mailed at least 30 days but not more than 60 days before the Redemption Date to each Holder of Securities to be redeemed at the Holder’s registered address. If
money sufficient to pay the Redemption Price of all Securities (or portions thereof) to be redeemed on the Redemption Date is deposited with the Paying Agent prior to or on the Redemption Date, immediately after such Redemption Date interest ceases
to accrue on such Securities or portions thereof. Securities in denominations larger than $1,000 of principal amount may be redeemed in part but only in integral multiples of $1,000 of principal amount. 
 8. Conversion. 
 Subject to and in compliance with the
provisions of the Indenture, a Holder is entitled, at such Holder’s option, to convert the Holder’s Security (or any portion of the principal amount thereof that is $1,000 or an integral multiple of $1,000), into fully paid and
nonassessable shares of Common Stock at the Conversion Rate in effect at the time of conversion, subject to the Company’s right to deliver cash in lieu of Common Stock. 
 A Security in respect of which a Holder has delivered a Fundamental Change Purchase Notice, exercising the option of such Holder to require the Company
to purchase such Security, may be converted only if such Fundamental Change Purchase Notice is withdrawn in accordance with the terms of the Indenture. 
 The initial Conversion Rate is 69.8348 shares per $1,000 principal amount of securities, subject to adjustment in certain events described in the Indenture. No fractional shares of Common Stock shall be issued upon
conversion of any Security. A Holder that surrenders Securities for conversion will receive cash in lieu of any fractional share of Common Stock. 
 To surrender a Security for conversion, a Holder must (i) complete and manually sign the conversion notice below (or complete and manually sign a facsimile of such notice), (ii) deliver such completed notice and surrender the
Security to the Conversion Agent and, (iii) pay all funds required and furnish appropriate endorsements and transfer documents and (iv) pay any transfer or similar tax, if required by the Indenture. 
  

 R-4 

 If the Company (i) is a party to a consolidation, merger or binding share exchange,
(ii) reclassifies the Common Stock or (iii) conveys, transfers or leases its properties and assets substantially as an entirety to any Person, the right to convert a Security into shares of Common Stock shall be changed into a right to
convert it into securities, cash or other assets of the Company or such other Person, in each case in accordance with the Indenture. 
 The
Company may elect to deliver either shares of its Common Stock, cash or a combination of cash and shares of Common Stock in satisfaction of the Company’s Conversion Obligation. The Company shall notify the Holder or Holders, as the case may be,
through the Trustee of the method the Company chooses to satisfy its Conversion Obligation, (i) in the Company’s Notice of Redemption, if the Company has called the Securities for redemption, (ii) 26 Trading Days immediately preceding
Stated Maturity in respect of Securities to be converted during the period beginning 25 Trading Days immediately preceding the Stated Maturity and ending one Trading Day immediately preceding Stated Maturity, and (iii) no later than three
Trading Days immediately following the date of conversion in all other cases. If the Company elects to satisfy any portion of its Conversion Obligation by delivering cash, the Company shall specify in such notice the portion to be paid in cash
either as a percentage of the Conversion Obligation or as the lesser of (a) a fixed dollar amount and (b) the Conversion Value. The Company shall treat all Holders converting on the same Trading Day in the same manner. The Company shall
not have any obligation to satisfy Conversion Obligations arising on different Trading Days in the same manner. 
 At any time prior to the
26th Trading Day preceding the Stated Maturity, the Company may irrevocably elect, in its sole discretion without the consent of the Holders of the Notes, by written notice to the Trustee and the Holders of the Notes, to satisfy in cash the
Conversion Obligation with respect to the principal amount of Notes to be converted after the date of such election, with any remaining amount of the Conversion Obligation to be satisfied in shares of Common Stock. The settlement amount will be
computed as described under Section 9.13(a)(iii) of the Indenture, using the $1,000 as the fixed dollar amount per $1,000 principal amount of Notes of the Conversion Obligation to be satisfied in cash. 
 9. Denominations; Transfer; Exchange. 
 The Securities
are in fully registered form, without coupons, in denominations of $1,000 of principal amount and integral multiples of $1,000. A Holder may transfer or exchange Securities in accordance with the Indenture. The Registrar may require a Holder, among
other things, to furnish appropriate endorsements and transfer documents and to pay any taxes and fees required by law or permitted by the Indenture. The Registrar need not transfer or exchange any Securities selected for redemption (except, in the
case of a Security to be redeemed in part, the portion of the Security not to be redeemed) or any Securities in respect of which a Fundamental Change Purchase Notice has been given and not withdrawn (except, in the case of a Security to be purchased
in part, the portion of the Security not to be purchased) or to issue, register the transfer of, or exchange any Securities for a period of 15 days before the redemption date. 
  

 R-5 

 10. Persons Deemed Owners. 
 The registered Holder of this Security may be treated as the owner of this Security for all purposes. 
 11. Unclaimed
Money or Securities. 
 The Trustee and the Paying Agent shall return to the Company upon written request any money held by them for the
payment of any amount with respect to the Securities that remains unclaimed for two years, subject to applicable unclaimed property law. After return to the Company, Holders entitled to the money or securities must look to the Company for payment as
general creditors unless an applicable abandoned property law designates another Person. 
 12. Amendment; Waiver. 
 Subject to certain exceptions set forth in the Indenture, (i) the Indenture or the Securities may be amended with the written consent of the Holders
of at least a majority in aggregate principal amount of the outstanding Securities and (ii) certain Defaults may be waived with the written consent of the Holders of a majority in aggregate principal amount of the outstanding Securities. The
Indenture and the Securities may also be amended by the Company and the Trustee, without the consent of any Holder, in certain circumstances set forth in the Indenture; provided, that certain provisions of the Indenture and the Securities may
not be amended without the consent of each affected Holder. 
 13. Defaults and Remedies. 
 If any Event of Default with respect to Securities shall occur and be continuing, the principal of all the Securities may be declared due and payable in
the manner and with the effect provided in the Indenture. 
 14. Trustee Dealings with the Company. 
 Subject to certain limitations imposed by the TIA, the Trustee under the Indenture, in its individual or any other capacity, may become the owner or
pledgee of Securities and may otherwise deal with and collect obligations owed to it by the Company or its Affiliates and may otherwise deal with the Company or its Affiliates with the same rights it would have if it were not Trustee. 
 15. No Recourse Against Others. 
 A director, officer,
employee or shareholder, as such, of the Company shall not have any liability for any obligations of the Company under the Securities or the Indenture or for any claim based on, in respect of or by reason of such obligations or their creation. By
accepting a Security, each Securityholder waives and releases all such liability. The waiver and release are part of the consideration for the issue of the Securities. 
  

 R-6 

 16. Treatment of Securities. 
 Each holder, by acceptance of a Security, and beneficial owner, by acceptance of a beneficial ownership interest in a Security, agrees to treat the Securities as indebtedness of the Company for U.S. federal income tax
purposes and to not take any action inconsistent with such treatment. 
 17. Authentication. 
 This Security shall not be valid until an authorized signatory of the Trustee manually signs the Trustee’s Certificate of Authentication on the other
side of this Security. 
 18. Abbreviations. 
 Customary abbreviations may be used in the name of a Securityholder or an assignee, such as TEN COM (=tenants in common), TEN ENT (=tenants by the entireties), JT TEN (=joint tenants with right of survivorship and not as tenants in common),
CUST (=custodian), and U/G/M/A (=Uniform Gift to Minors Act). 
 19. GOVERNING LAW. 
 THIS SECURITY AND THE INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK. 
 The Company will furnish to any Securityholder upon written request and without charge a copy of the Indenture which has in it the text of this Security.
Requests may be made to: 
 Nabi Biopharmaceuticals 
 5800 Park of Commerce Boulevard N.W. 
 Boca Raton, FL 33487 
 Attention: Chief Financial Officer 
 Facsimile No.: (561) 989-5801 
 20.
Registration Rights. 
 The Holders of any Restricted Security are entitled to the benefits of the Registration Rights Agreement, dated
as of April 19, 2005, among the Company and the Initial Purchasers, including the receipt of Liquidated Damages upon a registration default (as defined in such agreement). 
  

 R-7 

			
	 ASSIGNMENT FORM
	  	 CONVERSION NOTICE

	To assign this Security, fill in the form below:	  	To convert this Security into Common Stock of the Company, check the box
		
	I or we assign and transfer this Security to	  	To convert only part of this Security, state the principal amount to be converted (which must be $1,000 or an integral multiple of $1,000):
		
	(Insert assignee’s soc. sec. or tax ID no.)	  	$
		
	(Print or type assignee’s name, address and zip code)	  	If you want the stock certificate made out in another person’s name fill in the form below:
		
	and irrevocably appoint
                             agent to transfer this Security on the books of the Company. The agent
may substitute another to act for him.	  	  
 (Insert the other person’s soc. sec. or tax ID no.)

		
	Date:                                 Your Signature:	  	
		
	  
	  	  

		
	(Sign exactly as your name appears on the other side of this Security)	  	(Print or type other person’s name, address and zip code)
		
	Signature Guaranteed	  	
		
	  
	  	  

	 Participant in a Recognized Signature Guarantee
 Medallion Program
	  	

  

			
	By:	 	  

		 	Authorized Signatory

  

 R-8 

 SCHEDULE OF INCREASES AND DECREASES OF GLOBAL SECURITY 
 Initial Principal Amount of Global Security: ($0.00). 
  

									
	 Date
	  	 Amount of
Increase in
Principal
Amount
of
 Global Security
	  	 Amount of
Decrease
 in Principal
Amount
 of
Global
Security
	  	 Principal
Amount of
 Global Security
After
 Increase or
Decrease
	  	 Notation by
Registrar
 or Security
Custodian

  

 R-9Severance Agreement

 Exhibit 10.20 
 January 13, 2006 
 Mr. H. LeRoux Jooste 
 9455 Bridgebrook Drive 
 Boca Raton, Fl 33496 
  

	Re:	Separation of Employment  

 Dear
LeRoux: 
 As you know, Nabi Biopharmaceuticals (“Nabi”) has terminated your employment with Nabi effective February 28, 2006
(the “Effective Date”). This letter agreement (the “Agreement”) will confirm the details of your separation from Nabi. 
  

	1.	Services. From the date hereof through the Effective Date, you shall provide such services to Nabi as Nabi shall request. 

  

	2.	Resignation. You have resigned as an officer of Nabi, and as an officer or director of any of Nabi’s subsidiaries in which you may serve in that capacity, effective
January 13, 2006. 

  

	3.	Severance. Provided that you do not revoke this Agreement as provided in Section 10 below and you comply with the other terms and provisions of this Agreement and with
Sections 9 and 10 of your Employment Agreement, you shall receive Severance benefits of ten (10). 

 You hereby confirm that
notwithstanding Section 8(D) of the Employment Agreement, your Option to purchase 160,000 shares of Nabi Common Stock granted pursuant to the option agreement dated December 20, 2004 shall expire and terminate on the Effective Date.

 You should be aware of the potential characterization of Severance Pay as non-qualified deferred compensation under the American Jobs
Creation Act. Notwithstanding that, Nabi has agreed with you to make a ten (10) month lump sum payment minus appropriate deductions to include health benefit premiums on March 10, 2006. The gross payment will be $253,666.67 and represents
ten (10) months pay plus ten (10) months of auto allowance. 
 You should consult with your tax advisor to consider how the American
Jobs Creation Act and the related regulations and other applicable tax laws affect your severance benefits. 
 During the period of your
severance your health benefits will continue in the same manner as existed during your employment. You will be sent information to coordinate the appropriate COBRA requirements with this health benefits continuation. 

	4.	Non-Disparagement. You agree that you will not make any communication, oral or written, that disparages, criticizes or otherwise reflects adversely upon Nabi or any of its
shareholders, employees, representatives and agents, past or present, except if testifying truthfully under oath pursuant to subpoena or other legal process. Nabi agrees to instruct its executive officers not to make any communication, oral or
written, that disparages you. 

  

	5.	Release. For and in consideration of the representations of Nabi set forth herein, and intending to be legally bound, you hereby release Nabi and its subsidiaries and their
respective shareholders, directors, officers, employees, representatives, and agents, past or present, and its and their respective successors and assigns, heirs, executors, and administrators, from any and all actions, suits, and claims which you
ever had, now have, or which your heirs, executors or administrators may have, up to and including the date on which you execute this Agreement. Particularly, but without limitation, you release any claims arising from or relating in any way to your
employment relationship or the termination of your employment relationship with Nabi, including any claims under any federal, state or local laws, including Title VII of the Civil Rights Act of 1964, as amended, the Age Discrimination in Employment
Act, the Americans with Disabilities Act, the Employee Retirement Income Security Act, and the Family and Medical Leave Act, any common law contract or tort claims now or hereafter recognized, and all claims for legal fees and costs.

 For the purposes of implementing a full and complete release of claims, you expressly acknowledge that this Agreement is
intended to include, without limitation, all claims described in this Section 5 herein, whether known or unknown, and that this Agreement contemplates the extinction of all such claims. You expressly waive any right to assert after signing this
Agreement that any such claim has, through ignorance or oversight, been omitted from the scope of the Agreement. 
 Nothing contained in this
Section 5 shall affect your right to indemnification for any period while you were serving as an officer of Nabi. 
  

	6.	Governing Law. This Agreement shall be subject to and governed by and in accordance with the laws of the State of Florida, without regard to conflict of laws principles.

  

	7.	Interpretation. Neither the fact that this offer for severance has been made or that this Agreement has been entered into, nor any provisions of this Agreement, shall be
construed as an admission by Nabi or any of its shareholders, agents, employees, or representatives, past or present, or by you that it or they or you violated any law or regulation or any other legal or equitable obligation it or they or you have
or ever had to each other. 

  

	8.	No Obligation to Re-employ. You agree that Nabi is under no obligation to rehire or re-employ you in the future. 

  

	9.	Return of Property. You agree to return to Nabi on or before the Effective Date all property of Nabi used or obtained by you in connection with your employment that is in
your possession or control. 

  

 - 2 - 

	10.	Revocation. You have the right to revoke this Agreement within seven (7) days of its execution by giving written notice of such revocation by hand-delivery or fax to
William E. Vandervalk, Vice President, Human Resources, Nabi Biopharmaceuticals, 5800 Park of Commerce Blvd., N.W., Boca Raton, FL 33487 (Fax No. 561.989.5874). In the event of such revocation, you shall not be entitled to receive the severance
benefits set forth above. 

  

	11.	Amendment. This Agreement cannot be amended orally or by any course of conduct or dealing and may only be amended or any of its provisions waived by a written agreement
signed by you and Nabi. 

  

	12.	Entire Agreement. When accepted by you, this Agreement and Sections 9, 10, 11 and 12 of the Employment Agreement set forth the entire agreement between you and Nabi and fully
supersede any and all prior agreements or understandings between you and Nabi pertaining to the subject matter thereof. 

  

	13.	Nabi Representation. Nabi represents that as of the date hereof, none of its executive officers knows of any claims or causes of action of whatever kind or nature that Nabi
has against you that arise on or before the date hereof. 

 If this Agreement is acceptable to you, please indicate your
agreement by signing and dating the enclosed copy of this Agreement and returning it to be received by me, on or before February 6, 2006, during which time you are advised to consult with an attorney. In the event that you fail to execute and
return this Agreement to me, on or before the close of business February 6, 2006, this Agreement will be of no further force and effect, and neither you nor Nabi will have any rights or obligations hereunder. 
  

	
	Sincerely,
	
	 /s/ Joseph S. Johnson

	Senior Vice-President People, Process & Technology

  

	cc:	Payroll/Human Resources 

 I expressly agree to accept the
Severance Agreement set forth above and verify that I am entering this Agreement knowingly and voluntarily, without any coercion or duress. I acknowledge that I was given adequate time to review this letter and that I was advised to obtain legal
advice from an attorney regarding its terms. I understand the contents of this Agreement, and agree to all its terms and conditions including the release of all claims contained in Section 5. 
  

					
	Date: January 17, 2006	 	Signed:	 	 /s/ LeRoux Jooste

  

 - 3 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00098-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00098-of-00352.parquet"}]]